Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver
Anurag Lavekar, Dhananjay Raje, Aarsha Sadar, Tanuja Manohar, Kavutharapu Sri Manjari, Pradeep T Satyanarayana
Cirrhosis, Liver disorders, Model for end-stage liver disease, Readmission
Citation Information :
Lavekar A, Raje D, Sadar A, Manohar T, Manjari KS, Satyanarayana PT. Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver. Euroasian J Hepatogastroenterol 2019; 9 (2):71-77.
Background: The rate of readmission to the hospital and mortality within 3 months is used as a quality measure for hospitalized patients with advanced liver disease; however, the topic has not been studied adequately under Indian context. Materials and methods: This study was a longitudinal study conducted from March 2017 to March 2018. Patients admitted with liver cirrhosis at inpatient hepatology service in Tertiary Health Care Centre, Mysore, India, were included for the study. A total of 232 patients were studied and their demographic, clinical, biochemical parameters along with readmission status and outcomes within 3 months of observation were recorded. The effect of these factors on readmission and mortality was studied through multivariate logistic regression. Results: The risk of readmission within 3 months was significantly associated with the presence of hydrothorax, hepatorenal syndrome (HRS), and portal vein thrombosis (PVT). Maddrey's discriminant function (DF), model for end-stage liver disease (MELD) score, and the Child–Turcotte–Pugh (CTP) C grade also significantly increased the odds of readmission. The area under curve (AUC) for DF and MELD were 0.927 and 0.928, respectively. Both DF and MELD significantly increased the odds of mortality. Conclusion: The present study revealed that the parameters such as MELD and DF score and complications such as hydrothorax, HRS, and PVT are the most predictive indicators of cirrhosis complication to ascertain the rate of readmission and mortality within 3 months of patient discharge.
Melato M, Sasso F, Zanconati F. Liver cirrhosis and liver cancer. A study of their relationship in 2563 autopsies. Zentralbl Pathol 1993;139(1):25–30.
Graudal N, Leth P, Marbjerg L, et al. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med 1991;230(2):165–171. DOI: 10.1111/j.1365-2796.1991.tb00425.x.
Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008;12(4):733–746. DOI: 10.1016/j.cld.2008.07.007.
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 1997;349(9064):1498–1504. DOI: 10.1016/S0140-6736(96)07492-2.
Talwalkar JA. Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis. Gastroenterology 2006;130(3):1005–1007. DOI: 10.1053/j.gastro.2005.11.055.
Nguyen GC, Segev DL, Thuluvath PJ. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol 2007;5(9):1092–1099. DOI: 10.1016/j.cgh.2007.04.027.
Institute of Medicine (U.S.). Crossing the quality chasm: a new health system for the 21st century. Washington, D.C.: National Academy Press; 2001. Committee on Quality of Health Care in America.
Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with post discharge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004;291(11):1358–1367. DOI: 10.1001/jama.291.11.1358.
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154–e235. DOI: 10.1161/CIRCULATIONAHA.105.167586.
Volk ML, Tocco RS, Bazick J, et al. Hospital re-admissions among patients with decompensated cirrhosis. Am J Gastroenterol 2012;107(2):247–252. DOI: 10.1038/ajg.2011.314.
Berman K, Tandra S, Forssell K, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011;9(3):254–259. DOI: 10.1016/j.cgh.2010.10.035.
Ganesh S, Rogal SS, Yadav D, et al. Risk factors for frequent readmissions and barriers to transplantation in patients with cirrhosis. PLoS One 2013;8(1):e55140. DOI: 10.1371/journal.pone.0055140.
Seraj SM, Campbell EJ, Argyropoulos SK, et al. Hospital readmissions in decompensated cirrhotics: factors pointing toward a prevention strategy. World J Gastroenterol 2017;23(37):6868–6876. DOI: 10.3748/wjg.v23.i37.6868.
Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol 2016;14(8):1181–1188. DOI: 10.1016/j.cgh.2016.04.009.
Bajaj JS, Reddy KR, Tandon P, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology 2016;64(1):200–208. DOI: 10.1002/hep.28414.
Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 2005;42(Suppl 1):S100–S107. DOI: 10.1016/j.jhep.2004.11.015.
Patel R, Lotlikar MS. Predictors of 1-month and 3-months hospital readmissions in decompensated cirrhosis in India. J Clin Exp Hepatol 2017;7(1):S53. DOI: 10.1016/j.jceh.2017.05.100.
Daswani R, Kumar A, Anikhindi SA, et al. Predictors of 90-day mortality in patients with severe alcoholic hepatitis: experience with 183 patients at a tertiary care center from India. Indian J Gastroenterol 2018;37(2):141–152. DOI: 10.1007/s12664-018-0842-0.
Kartoun U, Corey KE, Simon TG, et al. The MELD-plus: a generalizable prediction risk score in cirrhosis. PLoS One 2017;12(10):e0186301. DOI: 10.1371/journal.pone.0186301.
Tapper EB, Finkelstein D, Mittleman MA, et al. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology 2015;62(2):584–590. DOI: 10.1002/hep.27830.
Sharma B, Raina S, Marwah R, et al. A follow-up study on adult patients with cirrhosis recruited in an open cohort from the hills of Himachal Pradesh. Int J Health Allied Sci 2016;5:24–27. DOI: 10.4103/2278-344X.173879.
Bhattacharyya M, Barman NN, Goswami BB. Clinical profile of cirrhosis of liver in a tertiary care hospital of Assam, North East India. IOSR J Dent Med Sci 2016;15(1):21–27.
Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. J Investig Med 2014;62(7):920–926. DOI: 10.1097/JIM.0000000000000106.
Chen CY, Wu CJ, Pan CF, et al. Influence of age on critically Ill patients with cirrhosis. Int J Gerontol 2015;9:233–238. DOI: 10.1016/j.ijge.2014.10.003.
Angele MK, Pratschke S, Chaudry IH. Does gender influence outcomes in critically ill patients? Crit Care 2012;16(3):129. DOI: 10.1186/CC11365.
Kalaitzakis E, Josefsson A, Björnsson E. Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC Gastroenterol 2008;8:46. DOI: 10.1186/1471-230X-8-46.
Saffouri E, Lim ES, Kim SW, et al. Short-term changes in liver tests predict long-term mortality. Frontline Gastroenterol 2016;7(4): 234–239. DOI: 10.1136/flgastro-2015-100669.
Potts JR, Goubet S, Heneghan MA, et al. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther 2013;38(6):584–595. DOI: 10.1111/apt.12427.
Appenrodt B, Zielinski J, Brensing KA, et al. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis. Eur J Gastroenterol Hepatol 2009;21(12):1428–1432. DOI: 10.1097/MEG.0b013e32832ec16a.
Garbuzenko DV, Arefyev NO. Hepatic hydrothorax: an update and review of the literature. World J Hepatol 2017;9(31):1197–1204. DOI: 10.4254/wjh.v9.i31.1197.
Stine JG, Shah PM, Cornella SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis. World J Hepatol 2015;7(27):2774–2780. DOI: 10.4254/wjh.v7.i27.2774.
Peng Y, Qi X, Guo X. Child–Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore) 2016;95(8):e2877. DOI: 10.1097/MD.0000000000002877.
Sheth M, Riggs M, Patel T. Utility of the mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:2. DOI: 10.1186/1471-230X-2-2.
Luca A, Miraglia R, Maruzzelli L, et al. Early liver failure after transjugular intrahepatic portosystemic shunt in patients with cirrhosis with model for end-stage liver disease score of 12 or less: incidence, outcome, and prognostic factors. Radiology 2016;280(2):622–629. DOI: 10.1148/radiol.2016151625.